{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-039394","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.629841+00:00","generated_at":"2026-06-08T00:03:38.491048+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Twist Bioscience reports FY2023 revenue $245.1M (+20% YoY), net loss $3.60/sh; FY2024 guide $285-290M","bullets":["FY2023 revenue $245.1M, up 20% from $203.6M; orders $264M, up 17% from $226.4M.","FY2023 net loss attributable to common stockholders $204.6M ($3.60 per share), down from $217.9M ($4.04) prior year.","Q4 revenue $66.9M, up 17% YoY from $57.3M; Q4 net loss $46.2M ($0.81 per share).","Guidance: FY2024 revenue expected $285M-$290M, reflecting growth.","Recent highlights: signed Bayer antibody deal worth up to $188M milestones; launched Twist Express Genes with 5-7 day turnaround."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-039394","json":"https://secwatch.observer/filing/0001628280-23-039394.json","markdown":"https://secwatch.observer/filing/0001628280-23-039394.md","text":"https://secwatch.observer/filing/0001628280-23-039394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/twist-20231117.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:03:38.491048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a693badb8500a3803e5bd40063cca6dc1de4697","claim":"Twist Bioscience Corp reported Fiscal year ended September 30, 2023 results: revenue $245.1 million, net income -$204.6 million, EPS -$3.60 per share.","evidence_excerpt":"FISCAL 2023 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2023 grew to $264 million compared to $226.4 million for fiscal 2022. • Revenue : Total revenues for fiscal 2023 grew to $245.1 million compared to $203.6 million for fiscal 2022. • Cost of Revenues : Cost of revenues for fiscal 2023 grew to $155.4 million compared to $119.3 million for fiscal 2022. • Research and Development Expenses : Research and development expenses for fiscal 2023 decreased to $106.9 million compared to $120.3 million for fiscal 2022. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2023 decreased to $189.7 million compared to $212.9 million for fiscal 2022. • Net Loss: Net loss attributable to common stockholders for fiscal 2023 decreased to $204.6 million , or $3.60 per share, compared to $217.9 million , or $4.04 per share, for fiscal 2022. • Cash Position: As of September 30, 2023 , the company had $336.4 million in cash, cash equiva","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fiscal year ended September 30, 2023"},{"label":"Revenue","value":"$245.1 million"},{"label":"Net income","value":"-$204.6 million"},{"label":"EPS","value":"-$3.60 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6cb453b90b49dc330dd1cf92e040e694235219a3","claim":"Twist Bioscience Corp reported Full year Fiscal 2024 results: revenue $285 million to $290 million. Guidance initiated.","evidence_excerpt":"— Expect revenue in the range of $285 million to $290 million for full year Fiscal 2024 --","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year Fiscal 2024"},{"label":"Revenue","value":"$285 million to $290 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7c2b3d6f6ddad49c89e7d86d207f996fc196411c","claim":"Twist Bioscience Corp reported Three months ended September 30, 2023 results: revenue $66.9 million, net income -$46.2 million, EPS -$0.81 per share.","evidence_excerpt":"FISCAL 2023 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2023 grew to $71.1 million compared to $62.1 million for the same period of fiscal 2022 . • Revenue: Total revenues for the fourth quarter of fiscal 2023 grew to $66.9 million compared to $57.3 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2023 increased to $42.4 million compared to $31.6 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2023 decreased to $23.7 million compared to $29.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2023 decreased to $47.4 million compared to $54.2 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the f","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023039394/0001628280-23-039394-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Three months ended September 30, 2023"},{"label":"Revenue","value":"$66.9 million"},{"label":"Net income","value":"-$46.2 million"},{"label":"EPS","value":"-$0.81 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}